Powered by
Cynata Advances Development of Cymerus(TM) MSCs for the Treatment of Asthma

- Final report of initial preclinical study confirms Cymerus(TM) MSCs have significant beneficial effects on all three key components of asthma: airway hyper-responsiveness, inflammation and airway remodelling

- Additional preclinical study expected to pave the way for a potential clinical trial

Australian stem cell and regenerative medicine company,Cynata Therapeutics Ltd(ASX: CYP), has signed an agreement with the Monash Lung Biology Network, a consortia involving researchers from

Sign up for unrestricted access to 200+ subscription services.
Already have an account? Click here to login.

RelSci News & Alerts gets you:

  • 10 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
  • Competitive business intelligence through daily data updates
  • Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox